Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies.

Abstract

BACKGROUND & AIMS:

Robust data on hepatocellular carcinoma (HCC) incidence among HIV/hepatitis B virus (HBV)-coinfected individuals on antiretroviral therapy (ART) are needed to inform HCC screening strategies. We aimed to evaluate the incidence and risk factors of HCC among HIV/HBV-coinfected individuals on tenofovir disoproxil fumarate (TDF)-containing ART in a large multi-cohort study.

METHODS:

We included all HIV-infected adults with a positive hepatitis B surface antigen test followed in 4 prospective European cohorts. The primary outcome was the occurrence of HCC. Demographic and clinical information was retrieved from routinely collected data, and liver cirrhosis was defined according to results from liver biopsy or non-invasive measurements. Multivariable Poisson regression was used to assess HCC risk factors.

RESULTS:

A total of 3,625 HIV/HBV-coinfected patients were included, of whom 72% had started TDF-containing ART. Over 32,673 patient-years (py), 60 individuals (1.7%) developed an HCC. The incidence of HCC remained stable over time among individuals on TDF, whereas it increased steadily among those not on TDF. Among individuals on TDF, the incidence of HCC was 5.9 per 1,000 py (95% CI 3.60-9.10) in cirrhotics and 1.17 per 1,000 py (0.56-2.14) among non-cirrhotics. Age at initiation of TDF (adjusted incidence rate ratio per 10-year increase: 2.2, 95% CI 1.6-3.0) and the presence of liver cirrhosis (4.5, 2.3-8.9) were predictors of HCC. Among non-cirrhotic individuals, the incidence of HCC was only above the commonly used screening threshold of 2 cases per 1,000 py in patients aged >45 years old at TDF initiation.

CONCLUSIONS:

Whereas the incidence of HCC was high in cirrhotic HIV/HBV-coinfected individuals, it remained below the HCC screening threshold in patients without cirrhosis who started TDF aged <46 years old.

LAY SUMMARY:

We investigated the incidence of hepatocellular carcinoma in HIV/hepatitis B virus-coinfected individuals from a large multi-cohort study in Europe. Over 32,673 patient-years, 60 individuals (1.7%) developed hepatocellular carcinoma. The incidence of hepatocellular carcinoma remained low in patients without cirrhosis, who started on tenofovir disoproxil fumarate when aged <46 years old.

• Authors: Gilles Wandeler, Etienne Mauron, Andrew Atkinson, Jean-François Dufour, David Kraus, Peter Reiss, Lars Peters, François Dabis, Jan Fehr, Enos Bernasconi, Marc van der Valk, Colette Smit, Lars K Gjærde, Jürgen Rockstroh, Didier Neau, Fabrice Bonnet, Andri Rauch, Swiss HIV Cohort Study, Athena Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort
• Journal: Journal of hepatology (J Hepatol) Vol. 71 Issue 2 Pg. 274-280 (08 2019) ISSN: 1600-0641 [Electronic] Netherlands
• PMID: 30965070 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Chemical References

• Anti-HIV Agents
• Hepatitis B Surface Antigens
• Tenofovir

Topics

• AIDS-Related Opportunistic Infections (drug therapy, virology)
• Adult
• Anti-HIV Agents (therapeutic use)
• Carcinoma, Hepatocellular (epidemiology)
• Coinfection (drug therapy, virology)
• Female
• Follow-Up Studies
• HIV
• Hepatitis B (drug therapy, virology)
• Hepatitis B Surface Antigens (analysis)
• Hepatitis B virus (immunology)
• Humans
• Incidence
• Liver Neoplasms (epidemiology)
• Male
• Middle Aged
• Prospective Studies
• Tenofovir (therapeutic use)